Uses of targeted oxidative therapeutic formulation in arteriosclerosis

   
   

The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.

L'utilisation d'une formulation pharmaceutique dans l'artériosclérose coronaire de traitement et une formulation pharmaceutique de deux-composant. La formulation pharmaceutique contient des espèces ou des produits peroxidic de réaction résultant de l'oxydation d'un alcène, tel que le géraniol, par un oxydant oxygène-contenant, tel que l'ozone ; un dissolvant pénétrant, tel que le sulfoxyde de dimithyl ; un colorant contenant un métal chélaté, tel que le hematoporphyrin ; et un composé redox aromatique, tel que le benzoquinone.

 
Web www.patentalert.com

< Systemic delivery of compounds through non-invasive bladder administration

< Anti-depression pharmaceutical composition containing polygala extract

> Benzothiophenes, formulations containing same, and methods

> Rat PTTG polypeptide and method for producing it

~ 00131